DiA Imaging Analysis, based in Beer Sheva, Israel, provides FDA-cleared and CE-marked AI-based ultrasound solutions that help clinicians capture the right images and automatically identify clinical abnormalities. Its vendor-neutral, cross-platform LVivo Toolbox is deployed on ultrasound devices and healthcare IT systems and currently serves thousands of end-users in more than 20 countries. The company announced an additional $14M in funding and plans to use the proceeds to expand its portfolio of solutions and grow its global presence in Asia, Europe and the U.S. It intends to pursue new and expanded partnerships with ultrasound vendors, PACS/Healthcare IT companies, resellers, and distributors. DiA has established channel and commercial partnerships with major healthcare technology providers and distributors including IBM Watson, Philips, GE Healthcare, and Konica Minolta. The company also added Dr. Diku Mandavia to its Board of Directors as an industry board member. DiA Imaging Analysis develops FDA- and CE-cleared cognitive image-processing software that provides fully automated ultrasound analysis, with its first product line focused on echocardiography. Its tools use advanced pattern recognition and machine-learning algorithms to automatically detect borders and motion and produce quantitative data for clinicians. The company integrates its software within ultrasound devices, healthcare IT systems and cloud platforms through partnerships with vendors including GE Healthcare, Neusoft Medical System and Google Cloud. DiA has reference sites at leading U.S. medical centers including Yale, Mount Sinai, RUSH, USF and UCSD, and its scientific advisory board is supported by cardiology and primary care ultrasound specialists. Founded by Hila Goldman Aslan (CEO), Michal Yaacobi (VP R&D) and Arnon Toussia-Cohen (VP BD), the Be'er Sheva–based company plans to expand its portfolio and build support teams in the United States, Europe and Asia. DiA closed a $5M funding round to support market penetration of its automated tools and further product development. DiACardio, founded in 2010 and based in Beer Sheva’s Hi-Tech Park, develops FDA- and CE-approved software that automatically evaluates heart function from ultrasound images. The company leverages new image-processing methods and proprietary algorithms to provide automated cardiac evaluation. DiACardio has 10 employees and has already obtained initial sales. It raised $1.95M in a post-seed financing to support growth. The company plans to use the funds to expand its automated toolbox to other areas of the heart and to grow its business in the US, Europe and emerging markets. The founding team includes Arnon Toussia-Cohen, Hila Goldman-Aslan, Michal Yaacobi, Dr. Noah Liel-Cohen and Prof. Hugo Guterman.

Total raised

$21M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2021